 In your most recent news, Steve, you say our lead products have delivered the strong growth we forecasted for 2022. I have to say congratulations. Where to start? Thank you very much, Tracy. Yes, we put a guidance earlier this week for the fourth quarter. Our previous guidance was 11 million. We've now up that to 12 and a half to 13 million. Our fourth quarter did end October 31st. So we have fairly high level of confidence that when all the numbers are tabulated, that that's where the revenues will be. And again, it's a combination there of our existing products, our asthma therapies that are growing Redesco, which is doing well, our blood thinner. And then the three new products that we licensed at the end of July, two of which are ophthalmic products or products for specific eye conditions. And the third product being a product for severe allergy called allergect. And I happen to have a little product right here and it's we have high expectations for this product as we do for all our products. And that's why the guidance went up. So let me back yet for a second. If you read the most recent news release, I'm so happy you could fit us in. You raised your Q4, but you also raised your full year 2022 revenue guidance. So respectfully, you told everybody here on investor Intel, you were going to do it and you've done it. So let's talk about your fiscal 22 revenue guidance being increased. Give us maybe a couple of the high points. You know what it's always nice to compare to prior periods gives a point of reference and if you look at our fiscal 21 we came in around 13.6 fiscal 22 we're coming in 100% higher. So we have to be happy about that but as I say to our colleagues at at value happiness last a few minutes and you can't sit on your laurels we have to continue moving forward and drive revenues even higher for 2023. But again, key products are delivering we have six we have a dozen products in total that we commercialized, but six of which we put significant marketing and and sales efforts behind. And those products are all growing at different rates but they are all growing so we're diversified portfolio before a portfolio that has quite a bit of upside past where we are now. When we do present to various bankers and what have we talked about having revenue potential over 200 million with the products that we have now. Now it's going to take several years to get to that level but it gives you a sense of the, the, the amplitude or the growth that can come from some of our products and that's the products we currently have not talking about anything else that might be in the pipeline. So further to your exceeding 100% compared to fiscal 2021 money doesn't seem to be enough for shareholders. Let's talk about the lives you're saving. Well they said we're changing a lot of lives and the first part if I talk about internally with going back 24 months we were 25 employees were now over 125 employees so we're very proud of building that building a Canadian owned pharma company that's doing good for patients and for physicians. And if we look at we talk about those those those stakeholders patients and physicians. We have a number of therapies that are doing quite well but one in particular and this is it here enters there. This is one of the most advanced asthma therapies on inhaled asthma therapies on the market today, destined for moderate to severe asthmatics and you're looking at about a million Canadians that do suffer. We're from asthma to the extent that they need to take their medication daily I'm not talking about those that need rescue medications or have asthma symptoms from time to time we're talking about people that on a daily basis need medication to be able to function during the day. A million Canadians. The statistics show that over half of these Canadians are not satisfied with their current therapy. So when you bring in a new drug like this newly launched by us just approved by Health Canada, a year and a half ago, which showed in clinical trials conducted by the Department of Health has noticed significantly better results than the existing standard of care it gives us a strong platform to reach out to physicians and to people who do suffer from asthma to say if your symptoms are not under control. You should consider enters there it's done very well and the anecdotal evidence we're getting back is very strong people comments are, I wish I would have been on this drug years ago, I can sleep through the night I can climb stairs I can exercise without asthma. This is, you know, suffer for those who do suffer from asthma it really reduces their quality of life and anything we can do to improve someone's quality of life, reduce their symptoms. I think we're doing good for our everyone shareholders employees and most and most for the patients who do suffer. So, life changing was how you would describe it I said life savings, but perhaps it's because being familiar with, you know, for instance, as, as Maddox, if they don't have their medication close by it can become quite dangerous is that not correct. Every year there's 70,000 plus Canadians that end up in in the emergency room, needing oxygen because their asthma symptoms and asthma symptoms can be things such as long function, tightness in the chest wheezing coffee, but it's almost like they come to a crescendo where the where the where the sufferer has to seek hospital help and another aspect of the clinical trials on enters there where it significantly reduced the number of so called exacerbations or asthma attacks. So this is important for people who suffer from asthma and our, you know, our calling is to get out there and talk to physicians and we currently access about 12,000 physicians in Canada. This is our target base for our sales team to go out there and demonstrate the clinical lab or show the clinical evidence that supports that and get them to use this product and we think it has a lot of benefits as I mentioned to people who are currently not satisfied or have issues with their current standard of care. I just want to say congratulations again. And one last question. I was talking to your investor relations head of your head of IR for Vallejo. And I was asking him what question do you wish investors would ask Steve when you set up these meetings with them what what do you want people to ask Steve. Well, I think the question that that people sometimes don't ask is, you know, where are you going in the future like the company is at a point in time today but that point in time and in a day you've passed that point in time so what is your ambition for this company where do you see it in in three to five years and clearly what we said two years ago. If we wind back your show and see early episodes we want to be one of the premier mid tier Canadian pharma companies mid tier being not a multinational, but certainly providing strong benefits to our shareholders and to and to patients. And I guess a lot of people are more fixated on well, what's your last quarter look like so it's more of a shorter term vision. I think when you look at Vallejo and you look at long term you can really get excited about this company. And the other thing I like is, you know, everything that we do not make predictions we talk about what we expect for the future and what we aspire to. But if you look back, I think a lot of what we've talked about in terms of aspiring to we've actually accomplished and I think that sets a good track record for us saying these, you know, we're on the right track, we're doing things it never works out exactly. You've got COVID that hits you and affects the way physicians interact with patients and sale. You've got other inflation, you've got higher interest rates, but the reality we've done a lot of what we said we were going to do and we continue to believe we're going to be one of the premier Canadian pharma companies. So I would just say to those that are not shareholders they keep an eye on us and hopefully at some point in the future you'll you'll feel inclined to to become a shareholder of Vallejo and to participate in our what is going to be an what's it been an exciting and will continue to be an exciting future. Well, you've just given me some very good ideas. Steve, as always, it's such a pleasure. Thank you so much for your update. Yeah, great. Great being here and we'll see you again soon.